GPMDB00325OtherJinyan Du, et al.InstrumentNot AvailableNot availableHuman_adenovirus_54,human_adenovirus_a,human_adenovirus_b,human_adenovirus_c,human_adenovirus_d,human_adenovirus_e,human_adenovirus_f,human_adenovirus_g,human_astrovirus,human_bocavirus,human_bocavirus_2,human_bocavirus_3,human_bocavirus_4,human_coronavirus_229e,human_coronavirus_hku1,human_coronavirus_nl63,human_coronavirus_oc43,human_cosavirus_a,human_cosavirus_b,human_cosavirus_d,human_cosavirus_e,human_enteric_coronavirus_4408,human_enterovirus_100,human_enterovirus_a,human_enterovirus_b,human_enterovirus_c,human_enterovirus_d,human_erythrovirus_v9,human_herpesvirus_1,human_herpesvirus_2,human_herpesvirus_3,human_herpesvirus_4_type_1,human_herpesvirus_4_type_2,human_herpesvirus_5,human_herpesvirus_6a,human_herpesvirus_6b,human_herpesvirus_7,human_herpesvirus_8_type_p,human_immunodeficiency_virus_1,human_immunodeficiency_virus_2,human_metapneumovirus,human_papillomavirus_fa75_ki88_03,human_papillomavirus_rtrx7,human_papillomavirus_type_10,human_papillomavirus_type_100,human_papillomavirus_type_101,human_papillomavirus_type_103,human_papillomavirus_type_104,human_papillomavirus_type_105,human_papillomavirus_type_108,human_papillomavirus_type_109,human_papillomavirus_type_112,human_papillomavirus_type_113,human_papillomavirus_type_16,human_papillomavirus_type_24,human_papillomavirus_type_26,human_papillomavirus_type_32,human_papillomavirus_type_34,human_papillomavirus_type_4,human_papillomavirus_type_41,human_papillomavirus_type_48,human_papillomavirus_type_49,human_papillomavirus_type_5,human_papillomavirus_type_50,human_papillomavirus_type_53,human_papillomavirus_type_60,human_papillomavirus_type_63,human_papillomavirus_type_6b,human_papillomavirus_type_7,human_papillomavirus_type_71,human_papillomavirus_type_88,human_papillomavirus_type_9,human_papillomavirus_type_92,human_papillomavirus_type_96,human_papillomavirus_type_98,human_papillomavirus_type_99,human_papillomavirus___1,human_papillomavirus___18,human_papillomavirus___2,human_papillomavirus___54,human_papillomavirus___61,human_papillomavirus___cand90,human_parainfluenza_virus_1,human_parainfluenza_virus_2,human_parainfluenza_virus_3,human_parechovirus,human_parvovirus_4,human_parvovirus_b19,human_picobirnavirus,human_respiratory_syncytial_virus,human_rhinovirus_a,human_rhinovirus_b,human_rhinovirus_c,human_tmev_like_cardiovirus,human_t_lymphotropic_virus_1,human_t_lymphotropic_virus_2,human_t_lymphotropic_virus_4,simian_adenovirus_a,simian_agent_12,simian_enterovirus_a,simian_enterovirus_sv19,simian_enterovirus_sv43,simian_enterovirus_sv6,simian_foamy_virus,simian_hemorrhagic_fever_virus,simian_human_immunodeficiency_virus,simian_immunodeficiency_virus,simian_immunodeficiency_virus_siv_mnd_2,simian_picornavirus_1,simian_picornavirus_17,simian_picornavirus_n125,simian_t_lymphotropic_virus_1,simian_t_lymphotropic_virus_2,simian_virus_12,simian_virus_40,simian_virus_41,simian_virus_5, Human_female19098899Golub@broad.mit.eduhttp://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023615http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023616http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023613http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023614http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023611http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023612http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023598http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023599http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023610http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023596http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023597http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023594http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023595http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023592http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023593http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023590http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023591http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023618http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023604http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023605http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023602http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023603http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023589http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023600http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023601http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023587http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023588http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023585http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023586http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023583http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023584http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023608http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023609http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023606http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023607The Broad Institute of Harvard University and Massachusetts Institute of TechnologyNot availableGPMDBThe aberrant activation of tyrosine kinases represents an important oncogenic mechanism, and yet the majority of such events remain undiscovered. Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase-activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo. Testing of dasatinib-resistant tyrosine kinase alleles confirmed that SRC is indeed the relevant target of dasatinib, which inhibits many tyrosine kinases. These studies establish the feasibility of tyrosine kinome-wide phosphorylation profiling and point to SRC as a possible therapeutic target in glioblastoma.Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.Du Jinyan J,Bernasconi Paula P,Clauser Karl R KR,Mani D R DR,Finn Stephen P SP,Beroukhim Rameen R,Burns Melissa M,Julian Bina B,Peng Xiao P XP,Hieronymus Haley H,Maglathlin Rebecca L RL,Lewis Timothy A TA,Liau Linda M LM,Nghiemphu Phioanh P,Mellinghoff Ingo K IK,Louis David N DN,Loda Massimo M,Carr Steven A SA,Kung Andrew L AL,Golub Todd R TR,Du Jinyan J, Bernasconi Paula P, Clauser Karl R KR, Mani D R DR, Finn Stephen P SP, Beroukhim Rameen R, Burns Melissa M, Julian Bina B, Peng Xiao P XP, Hieronymus Haley H, Maglathlin Rebecca L RL, Lewis Timothy A TA, Liau Linda M LM, Nghiemphu Phioanh P, Mellinghoff Ingo K IK, Louis David N DN, Loda Massimo M, Carr Steven A SA, Kung Andrew L AL, Golub Todd R TRpara Tyrosine, bead, 2-Amino-3-(p-hydroxyphenyl)propionic acid, Phosphorylations, [M]Glioblastoma NOS (morphologic abnormality), para-Tyrosine, Giant Cell, Grade IV, Astrocytomas, Phosphotransferases, phosphorylation, Tyrosine, Glioblastoma (morphologic abnormality), Grade IV Astrocytic Neoplasm, Spongioblastoma Multiforme, disease management., tirosina, NOS, Kinase, p60-Src, Giant Cell Glioblastomas, treatment, Transphosphorylases, Glioblastoma, SRC1, Kinases, Grade IV Astrocytic Tumor, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, L-isomer, c-SRC, Glioblastomas, GBM, AW259666, [M]Glioblastoma NOS, GBM - Glioblastoma multiforme, C9H11NO3, Giant Cell Glioblastoma, Astrocytoma, L isomer, Glioblastoma Multiforme, ASV, no ICD-O subtype, Grade IV Astrocytomas, L Tyrosine, no ICD-O subtype (morphologic abnormality), Tyr, L-Tyrosine, GLM - Glioblastoma multiforme, Grade IV Astrocytoma, Tyrosin, pp60c-src, Glioblastoma NOS (morphologic abnormality), ATP Phosphotransferases, GBM (Glioblastoma), ATPpara Tyrosine, Sprycel, HSN1E, A4, Homo sapiense, Tumor, Astrocytomas, phosphorylation, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Glioblastoma (morphologic abnormality), Homo sapien, Method, Homo sapians, Kinase, RCB0027, Rad9-Hus1-Rad1 (9-1-1) clamp complex, InChI=1/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5, 24, 25, 26, me75, Homo sapients, 28, activation inducer molecule, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, [M]Glioblastoma NOS, Giant Cell Glioblastoma, D17Mit170, T1, Astrocytoma, ASV, dasatinibum, Methodological Studies, Homo sapience, no ICD-O subtype (morphologic abnormality), Tyr, ATP Phosphotransferases, Home sapiens, ATP, Diagnostic Findings, BMS Dasatinib, Tumors, SIGNS SYMPTOMS, Trans docos-13-enoic Acid, non-developmental growth., DESC, 2-Amino-3-(p-hydroxyphenyl)propionic acid, para-Tyrosine, Procedure, Giant Cell, Tl3, Tl2, tumours, Fsrg1, Tyrosine, RING3, Homo sapian, 32)(H, FSRG1, NOS, BMS 354825, finances, activation, early T-cell activation antigen p60, K562 cell, ADCADN, Transphosphorylases, Glioblastoma, growth pattern, SRC1, L-isomer, c-SRC, salaries, GBM, GBM - Glioblastoma multiforme, Methodological, beta Trypsin, Methodological Study, Homo sapines, human, L isomer, DMDA, Grade IV Astrocytomas, L-Tyrosine, GLM - Glioblastoma multiforme, InChIKey=ZBNZXTGUTAYRHI-VEORKLDJCJ, financial management, Glioblastoma NOS (morphologic abnormality), 6-11H2, RCB1897, Clinical Finding, Fsrg-1, CD69, GBM (Glioblastoma), Nat, NAT, D17H6S113E, human being, Procedures, Neoplasms, EA1, K-562, MLR-3, Grade IV, FSH, TYPE, Symptoms and Signs, NEOPL, (H, DAGA4, 354825, method, Homo spaiens, Spongioblastoma Multiforme, AIM, BMS-354825, method used in an experiment, Studies, Low, Finding, MAM, p60-Src, early activation antigen CD69, Giant Cell Glioblastomas, SCG3, malignant tumour, K-562 cell, Fatty Acid 22:1 n-9 trans, beta-Trypsin, malignant neoplasia, tumour, Ring3, financing, man, 27)/f/h27-28H, Brassidic Acid, Study, funding, Glioblastoma Multiforme, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), leukocyte surface antigen Leu-23, Fatty Acid trans 22:1 n-9, L Tyrosine, BMS, Homo sampiens, C-type lectin domain family 2 member C, Grade IV Astrocytoma, Tyrosin, pp60c-src, Neoplastic Growth, Cancer, fees, data, 12-13, bead, cou, Malignant Neoplasm, DNMT, Phosphorylations, [M]Glioblastoma NOS (morphologic abnormality), MCMT, Phosphotransferases, LGMD2C, BMS354825, BL-AC/P26, K562, Signs and Symptoms, Grade IV Astrocytic Neoplasm, Lr, tirosina, C22H26ClN7O2S, 31H, AW228947, mKIAA4005, Homo sapeins, CXXC9, N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1, D6S113E, 1-2H3, DMDA1, Kinases, Grade IV Astrocytic Tumor, N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, RNF3, Rnf3, Frg-1, n-9 trans, Tripcellim, Glioblastomas, Humo sapiens, AW259666, (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, patient, Cancers, C9H11NO3, malignant tumor, plan specification, Trypure, CCC, cost, Homo spiens, "human" EXACT genbank_common_name [], no ICD-O subtype, GP32/28, SCARMD2, Bra, 3-thiazole-5-carboxamide, CLEC2C, NEOPLASMS BENIGN, Neoplasia, C22:1para Tyrosine, bead, 2-Amino-3-(p-hydroxyphenyl)propionic acid, Phosphorylations, [M]Glioblastoma NOS (morphologic abnormality), para-Tyrosine, Giant Cell, Grade IV, Astrocytomas, Phosphotransferases, phosphorylation, Tyrosine, Glioblastoma (morphologic abnormality), Grade IV Astrocytic Neoplasm, Spongioblastoma Multiforme, disease management., tirosina, NOS, Kinase, p60-Src, Giant Cell Glioblastomas, treatment, Transphosphorylases, Glioblastoma, SRC1, Kinases, Grade IV Astrocytic Tumor, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, L-isomer, c-SRC, Glioblastomas, GBM, AW259666, [M]Glioblastoma NOS, GBM - Glioblastoma multiforme, C9H11NO3, Giant Cell Glioblastoma, Astrocytoma, L isomer, Glioblastoma Multiforme, ASV, no ICD-O subtype, Grade IV Astrocytomas, L Tyrosine, no ICD-O subtype (morphologic abnormality), Tyr, L-Tyrosine, GLM - Glioblastoma multiforme, Grade IV Astrocytoma, Tyrosin, pp60c-src, Glioblastoma NOS (morphologic abnormality), ATP Phosphotransferases, GBM (Glioblastoma), ATPpara Tyrosine, Sprycel, insensitive, HSN1E, A4, Homo sapiense, Tumor, Astrocytomas, phosphorylation, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Glioblastoma (morphologic abnormality), Homo sapien, Method, Homo sapians, Kinase, InChI=1/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5, 24, 25, 26, me75, Homo sapients, 28, activation inducer molecule, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, [M]Glioblastoma NOS, Giant Cell Glioblastoma, D17Mit170, T1, Astrocytoma, ASV, dasatinibum, Methodological Studies, Homo sapience, no ICD-O subtype (morphologic abnormality), Tyr, Allele, ATP Phosphotransferases, Grade IV., Home sapiens, ATP, Diagnostic Findings, BMS Dasatinib, Tumors, SIGNS SYMPTOMS, Trans docos-13-enoic Acid, wide/broad, aberrant, DESC, 2-Amino-3-(p-hydroxyphenyl)propionic acid, para-Tyrosine, Procedure, Giant Cell, Tl3, Tl2, tumours, Tyrosine, Homo sapian, 32)(H, NOS, BMS 354825, activation, finances, early T-cell activation antigen p60, ADCADN, Transphosphorylases, Glioblastoma, resistant, growth pattern, SRC1, non-developmental growth, L-isomer, c-SRC, salaries, GBM, GBM - Glioblastoma multiforme, Methodological, Methodological Study, Homo sapines, human, L isomer, wide, DMDA, Grade IV Astrocytomas, L-Tyrosine, GLM - Glioblastoma multiforme, InChIKey=ZBNZXTGUTAYRHI-VEORKLDJCJ, financial management, Glioblastoma NOS (morphologic abnormality), 6-11H2, Clinical Finding, CD69, GBM (Glioblastoma), atypia, Allelomorphs, human being, Procedures, Neoplasms, EA1, broad, MLR-3, Grade IV, TYPE, Symptoms and Signs, NEOPL, (H, DAGA4, 354825, method, Homo spaiens, Spongioblastoma Multiforme, AIM, BMS-354825, method used in an experiment, Studies, atypical, Low, Finding, MAM, p60-Src, early activation antigen CD69, Giant Cell Glioblastomas, SCG3, malignant tumour, Fatty Acid 22:1 n-9 trans, malignant neoplasia, tumour, financing, man, 27)/f/h27-28H, Brassidic Acid, Allelomorph, Study, funding, Glioblastoma Multiforme, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), leukocyte surface antigen Leu-23, Fatty Acid trans 22:1 n-9, L Tyrosine, BMS, Homo sampiens, C-type lectin domain family 2 member C, Grade IV Astrocytoma, Tyrosin, pp60c-src, Neoplastic Growth, Cancer, fees, 12-13, bead, cou, Malignant Neoplasm, DNMT, Phosphorylations, defective, [M]Glioblastoma NOS (morphologic abnormality), MCMT, Phosphotransferases, LGMD2C, BMS354825, BL-AC/P26, Signs and Symptoms, Grade IV Astrocytic Neoplasm, Lr, tirosina, C22H26ClN7O2S, 31H, Homo sapeins, CXXC9, N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1, 1-2H3, DMDA1, Kinases, Grade IV Astrocytic Tumor, N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, n-9 trans, Glioblastomas, Humo sapiens, AW259666, (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, patient, Cancers, C9H11NO3, malignant tumor, plan specification, cost, Homo spiens, "human" EXACT genbank_common_name [], no ICD-O subtype, GP32/28, SCARMD2, Bra, 3-thiazole-5-carboxamide, CLEC2C, NEOPLASMS BENIGN, Neoplasia, C22:13205http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM11210023591dbgap_ncbi~0patentfamilies~0rfam~0merops~0complex-portal~0uniprot~0wormbaseparasite~0embl-covid19~0reactome~0emdb~0wgs_masters~0ebiweb_resources~0opentargets_genetics~0biomodels_all~0ipd-mhc~0ebiweb_teams~0taxonomy~0genome_assembly~0sc-experiments~0ebiweb_people~0enzymeportal_enzymes~0ipd-nhkir~0cellosaurus~0pdbe~0chebi~0patentproteins~0interpro7~0uniref~0chembl~0pdbekb~0gpcrdb~0hgnc~0sc-genes~0intact~0rhea~0ebiweb_training~0alphafold~0imgt-hla~0patentnucleotides~0ensemblroot~0eva_studies~0non-coding~0europepmc~0pubmed~1identifiers_registry~0pdbechem~0massive~1hpa-covid19~0eva-variants-covid19~0biosamples~0gwas_catalog~0biotools~0tls_masters~0mesh~0coding~0sra~0opentargets~0efo~0embl-pathogen~0human_diseases~0geo_datasets~0embl~0treefam~0project~1uniparc~0ols~0dgva~0intenz~0go~0tsa_masters~0biosamples-covid19~0ebiweb_corporate~0omim~0lrg~0earlycause-molecular-sequences~0ipd-kir~0empiar~0rnacentral~0orcid_data_claims~0gpmdb~2lineage-covid19~0metagenomics~0pfam~0varsite~00Resource Reanalysis0.00.00.009870450339296730.01.0falseBead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.Data from MASSIVE, [[http://proteomics.ucsd.edu/ProteoSAFe/datasets.jsp MSV000078499]]. File: K562_P060110_trypsin_09_19_ftt8_ccc_01.mzml. Published as part of Nat Biotechnol. 2009 Jan;27(1):77-83 . From the Abstract: {{i}} ... Here we describe a bead-based method for detecting phosphorylation of both wild-type and mutant tyrosine kinases in a multiplexed, high-throughput and low-cost manner. With the aim of establishing a tyrosine kinase-activation catalog, we used this method to profile 130 human cancer lines. Follow-up experiments on the finding that SRC is frequently phosphorylated in glioblastoma cell lines showed that SRC is also activated in primary glioblastoma patient samples and that the SRC inhibitor dasatinib (Sprycel) inhibits viability and cell migration in vitro and tumor growth in vivo ... {{/i}}2013-11-22GPM1121002359119098899MSV000078499